The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb
Open accessAbstract
Topical ophthalmic delivery of active ingredients can be achieved using cationic nanoemulsions. In the last decade, Novagali Pharma has successfully developed and marketed Novasorb, an advanced pharmaceutical technology for the treatment of ophthalmic diseases. This paper describes the main steps in the development of cationic nanoemulsions from formulation to evaluation in clinical trials. A major challenge of the formulation work was the selection of a cationic agent with an acceptable safety profile that would ensure a sufficient ocular surface retention time. Then, toxicity and pharmacokinetic studies were performed showing that the cationic emulsions were safe and well tolerated. Even in the absence of an active ingredient, cationic emulsions were observed in preclinical studies to have an inherent benefit on the ocular surface. Moreover, clinical trials demonstrated the efficacy and safety of cationic emulsions loaded with cyclosporine A in patients with dry eye disease. Ongoing studies evaluating latanoprost emulsion in patients with ocular surface disease and glaucoma suggest that the beneficial effects on reducing ocular surface damage may also extend to this patient population. The culmination of these efforts has been the marketing of Cationorm, a preservative-free cationic emulsion indicated for the symptomatic treatment of dry eye.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Drug Development and Industrial Pharmacy
Rhodes, C. T. (1995) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049509070870 · Cited by 1,263
Microencapsulation : methods and industrial applications
Benita, S. (1996) · Medical Entomology and Zoology · Cited by 806
Self-citationNanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells
Vinogradov, S. V., Bronich, T. K., & Kabanov, A. V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00245-9 · Cited by 775
HUNTER, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.008 · Cited by 456
Chitosan-based nanostructures: A delivery platform for ocular therapeutics
de la Fuente, M., Raviña, M., Paolicelli, P., Sanchez, A., Seijo, B., & Alonso, M. J. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.026 · Cited by 354
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers
Calvo, P., Vila-Jato, J. L., & Alonso, M. J. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00083-5 · Cited by 347
Ocular Preparations: The Formulation Approach
Pal Kaur, I., & Kanwar, M. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120003445 · Cited by 310
Ophthalmic drug delivery systems
Shell, J. W. (1984) · Survey of Ophthalmology · doi:10.1016/0039-6257(84)90168-1 · Cited by 291
Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use
Vandervoort, J., & Ludwig, A. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(03)00187-5 · Cited by 245
Cyclosporine A delivery to the eye: A pharmaceutical challenge
Lallemand, F., Felt-Baeyens, O., Besseghir, K., Behar-Cohen, F., & Gurny, R. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(03)00138-3 · Cited by 240
Self-citationThe potential of lipid emulsion for ocular delivery of lipophilic drugs
Shunmugaperumal, T., & Benita, S. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.033 · Cited by 167
Self-citationNovel drug delivery systems for glaucoma
Lavik, E., Kuehn, M. H., & Kwon, Y. H. (2011) · Eye · doi:10.1038/eye.2011.82 · Cited by 158
Cationic Vectors in Ocular Drug Delivery
Rabinovich‐Guilatt, L., Couvreur, P., Lambert, G., & Dubernet, C. (2004) · Journal of drug targeting · doi:10.1080/10611860400015910 · Cited by 139
Gershanik, T., & Benita, S. (1996) · Pharmaceutical Development and Technology · doi:10.3109/10837459609029889 · Cited by 109
Self-citationTransport mechanisms of the cornea: characterization of barrier permselectivity
Rojanasakul, Y., & Robinson, J. R. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90047-1 · Cited by 100
Polyethylenimine‐coated albumin nanoparticles for BMP‐2 delivery
Zhang, S., Wang, G., Lin, X., Chatzinikolaidou, Μ., Jennissen, H. P., Laub, M., & Uludağ, H. (2008) · Biotechnology Progress · doi:10.1002/btpr.12 · Cited by 91
Influence of Emulsion Droplet Surface Charge on Indomethacin Ocular Tissue Distribution
Klang, S. H., Abdulrazik, M., & Benita, S. (2000) · Pharmaceutical Development and Technology · doi:10.1081/pdt-100102035 · Cited by 80
Self-citationAcheampong, A., Shackleton, M., Tang-Liu, D. D.-S., Ding, S., Stern, M. E., & Decker, R. (1999) · Current Eye Research · doi:10.1076/ceyr.18.2.91.5381 · Cited by 78
Toxicity of nanomaterials to the eye
Prow, T. W. (2009) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.65 · Cited by 77
Muchtar, S., Almog, S., Torracca, M. T., et al. (2009) · Ophthalmic Research · doi:10.1159/000267160 · Cited by 76
Ocular drug delivery – a look towards nanobioadhesives
du Toit, L. C., Pillay, V., Choonara, Y. E., Govender, T., & Carmichael, T. R. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.542142 · Cited by 76
Hagigit, T., Abdulrazik, M., Orucov, F., Valamanesh, F., Lambert, M., Lambert, G., Béhar‐Cohen, F., & Benita, S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.013 · Cited by 73
Self-citationWang, J., Feng, S., Wang, S., & Chen, Z.-Y. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.026 · Cited by 69
Klang, S. H., Frucht‐Pery, J., Hoffman, A., et al. (1994) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1994.tb03254.x · Cited by 68
Masotti, A., Moretti, F., Mancini, F., Russo, G., Lauro, N. D., Checchia, P., Marianecci, C., Carafa, M., Santucci, E., & Ortaggi, G. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.066 · Cited by 60
Liang, H., Brignole‐Baudouin, F., Rabinovich‐Guilatt, L., Mao, Z., Riancho, L., Faure, M.-O., Warnet, J., Lambert, G., & Baudouin, C. (2008) · PubMed Central · Cited by 58
Intraocular penetration of topically applied cyclosporine.
Rl, K. (1988) · PubMed · Cited by 58
Optimization of Lipid Composition in Cationic Emulsion as In Vitro and In Vivo Transfection Agents
Kim, T. W., Chung, H., Kwon, I. C., Sung, H. C., & Jeong, S. Y. (2001) · Pharmaceutical Research · doi:10.1023/a:1011074610100 · Cited by 57
Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions
Sznitowska, M., Janicki, S., Dąbrowska, E. A., et al. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00034-9 · Cited by 50
Recent Patents on Ocular Drug Delivery Systems
Conway, B. R. (2008) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221108783331410 · Cited by 42
When nanotechnology meets the ocular surface
Bucolo, C., Maltese, A., & Drago, F. (2008) · Expert Review of Ophthalmology · doi:10.1586/17469899.3.3.325 · Cited by 42
Prevention of topical and ocular oxidative stress by positively charged submicron emulsion
Benita, S. (1999) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(99)80088-2 · Cited by 39
Self-citationLiang, H., Baudouin, C., Faure, M.-O., Lambert, G., & Brignole‐Baudouin, F. (2009) · PubMed Central · Cited by 33
The preparation of sustained release erythropoietin microparticle
Yeh, M., Chen, J.-L., Chiang, C., & Chang, Z.-Y. (2007) · Journal of Microencapsulation · doi:10.1080/02652040601058533 · Cited by 14
Acheampong, A., Shackleton, M., Lam, S., et al. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-5359-5_144 · Cited by 13
An Updated Patent Review on Ocular Drug Delivery Systems with Potential for Commercial Viability
Srivastava, R., & Pathak, K. (2011) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221111795471436 · Cited by 12
Cited by
Nanoemulsions: Formation, properties and applications
Gupta, A., Eral, H. B., Hatton, T. A., & Doyle, P. S. (2016) · Soft Matter · doi:10.1039/c5sm02958a · Cited by 1,633
TFOS DEWS II Management and Therapy Report
Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.006 · Cited by 1,422
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
Poloxamer 407/TPGS mixed micelles as promising carriers for cyclosporine ocular delivery
Grimaudo, M. A., Pescina, S., Padula, C., Santi, P., Concheiro, A., Alvarez-Lorenzo, C., & Nicoli, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00939 · Cited by 138
Shen, Y., Yu, Y., Chaurasiya, B., Li, X., Xu, Y., Webster, T., Tu, J., & Sun, R. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s173691 · Cited by 35
Metadata
- Authors
- Lallemand, F., Daull, P., Benita, S., Buggage, R., & Garrigue, J.-S.
- Venue
- Journal of Drug Delivery
- Publisher
- Hindawi Limited
- Published
- 2012-02-27
- Volume
- 2012
- Pages
- 1-16
- ISSN
- 2090-3014 (ISSN-L)
- 2090-3022
- OpenAlex
- W2107228338
- Cited by
- 314
- References
- 37
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.